콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

350R-1

Sigma-Aldrich

FoxP1 (SP133) Rabbit Monoclonal Antibody

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
12352203
NACRES:
NA.41

생물학적 소스

rabbit

Quality Level

100
500

결합

unconjugated

항체 형태

culture supernatant

항체 생산 유형

primary antibodies

클론

SP133, monoclonal

설명

For In Vitro Diagnostic Use in Select Regions (See Chart)

형태

buffered aqueous solution

종 반응성

human

포장

vial of 0.1 mL concentrate (350R-14)
vial of 0.5 mL concentrate (350R-15)
bottle of 1.0 mL predilute (350R-17)
vial of 1.0 mL concentrate (350R-16)
bottle of 7.0 mL predilute (350R-18)

제조업체/상표

Cell Marque

기술

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

동형

IgG

제어

DLBCL, lymph node, tonsil

배송 상태

wet ice

저장 온도

2-8°C

시각화

nuclear

유전자 정보

human ... FOXP1(27086)

일반 설명

Diffuse large B-cell lymphoma (DLBCL) represents different clinicopathologic entities which are difficult to separate using standard techniques. From the clinical standpoint, the introduction of immunochemotherapy in the treatment of DLBCL has dramatically improved the outcome of these patients compared with chemotherapy alone. Gene expression profiling (GEP) studies have shown that DLBCL can be reproducibly divided into the important subtypes of germinal center B-cell–like (GCB), activated B-cell–like (ABC), and unclassified DLBCL. It is beneficial to translate the GEP classification into protein expression by tumor cells through immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded tissues. A panel of antibodies: CD10, BCL6, MUM1/IRF4, GCET1, FoxP1, LMO2, and BCL2 has been used to determine GCB or ABC and each has different percentage thresholds for positive staining. Choi et al. demonstrated that the cases positive for GCET1 (≥ 80% of tumor cells) and MUM1/IRF4 (≥ 80%) and/or FoxP1 (≥ 80%) or negative for CD10 and BCL6 (≤ 30%) were assigned to the group. The cases positive for CD10 (≥ 30%), GCET1 (≥ 80%) without MUM1 expression, or positive for BCL6 without FoxP1 expression were classified as GCB. This study indicated the importance of FoxP1 in the subclassification of DLBCL. Choi et al then modified their approach to DLBCL subclassification by focusing on FoxP1. The tumors that are positive for both FoxP1 and GCET1 are assigned to GCB subgroup, but, if FoxP1 is positive and GCET1 is negative, the tumors belong to the ABC phenotype. If a case is FoxP1 negative but MUM-1/IRF4 positive, it still belongs to the ABC phenotype as long as CD10 is not expressed. This modified method emphasized the role of FoxP1, MUM1/IRF4, and GCET1 in the subclassification of DLBCL. The Choi′s algorithm had a very high concordance with the GEP results (87%). Therefore, FoxP1 is useful in subclassification of DLBCL and a high cutoff (≥80%) for FoxP1 is needed to achieve high specificity for the ABC subtype.

품질


IVD

IVD

IVD

RUO

결합

FoxP1 Positive Control Slides, Product No. 350S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

물리적 형태

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

제조 메모

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

기타 정보

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

법적 정보

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

적합한 제품을 찾을 수 없으신가요?  

당사의 제품 선택기 도구.을(를) 시도해 보세요.


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Further studies on biosynthesis of erythropoietin.
R Bandyopadhyay et al.
Indian journal of biochemistry & biophysics, 18(4), 241-244 (1981-08-01)
Andreas Rosenwald et al.
The New England journal of medicine, 346(25), 1937-1947 (2002-06-21)
The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival. Biopsy samples of diffuse large-B-cell lymphoma from
Paul N Meyer et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(2), 200-207 (2010-12-08)
Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify
Swerdlow, SH et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva: World Health Organization; 2008.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (2008)
H Hagberg et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 17 Suppl 4, iv31-iv32 (2006-05-17)
The multicentre phase III CORAL study aims to guide choice of salvage chemotherapy in diffuse large B-cell lymphoma (DLBCL) and assess the role of rituximab maintenance after autologous stem cell transplantation (ASCT). Patients are first randomised between ICE (ifosfamide, carboplatin

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.